USAID is the lead U.S. Government agency that works to end extreme global poverty and enable resilient, democratic societies to realize their potential.

**Neglected Tropical Diseases**

Neglected tropical diseases are intricately linked to poverty and inequality. They pose a crushing burden, particularly on the poorest, most marginalized and hard to reach populations. These diseases take a heavy human toll, causing chronic illness, blindness, and physical disfigurements. These diseases tighten their grip on people and families by exacerbating malnutrition, delaying cognitive development and lead to an appreciable loss of productivity.

The USAID Neglected Tropical Diseases Program targets the most prevalent neglected tropical diseases that have proven, cost-effective health interventions.

**Our Approach**

USAID invests the greatest portion of its funding in areas that have the greatest potential to achieve the World Health Organization 2020 NTD control and elimination goals.

**MAP the disease burden**

Mapping pinpoints the geographic distribution of diseases, showing exactly which communities are at risk. Through geographic information systems, diagnostics, smartphones and other tools, USAID and partners collect data that serves as a blueprint to design effective programs. This strong base of data enables countries to benefit from the drug donation program, accurately estimate drug quantities, and channel resources to the communities in need.

**DELIVER treatment to communities**

Large-scale treatment programs are the centerpiece of our work. USAID supports planning, logistics and community resource mobilization activities, working hand in hand with countries to deliver treatments through schools and community-based centers. This integrated approach, called mass drug administration, reaches more people in need and treats communities for multiple diseases at the same time.

**MEASURE the impact**

Measuring progress is an essential component of our program. USAID monitors program results and supports impact evaluations that show whether treatment programs are reducing prevalence levels to a point where it is no longer a public health threat and mass drug administration can be stopped.

**USAID also invests in complementary interventions that advance the WHO 2020 goals.**

**Provide care and treatment for disability**

USAID and country partners are working to alleviate or correct the morbidity, disability and disfigurement associated with NTDs through surgical support and limb care.

**Conduct Operational Research**

USAID works with other donors on operational research to document best practices, strengthen the evidence base for effective interventions and remove barriers to program implementation.

**Develop new tools and diagnostics**

USAID supports the development of diagnostic tools and new drugs that could speed up progress in achieving the World Health Organization 2020 targets for NTDs.
Over 10 years of results

<table>
<thead>
<tr>
<th>Year</th>
<th>Value of Drug Donations by Year</th>
<th>Number of Treatments Delivered by Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FY 2006 $404 million</td>
<td>Program Begins 36 million</td>
</tr>
<tr>
<td></td>
<td>2007 $507 million</td>
<td>2008 $577 million</td>
</tr>
<tr>
<td></td>
<td>2009 $686 million</td>
<td>2010 $949 million</td>
</tr>
<tr>
<td></td>
<td>2011 $1 billion</td>
<td>2012 $2.5 billion</td>
</tr>
<tr>
<td></td>
<td>2013 $2 billion</td>
<td>2014 $2.1 billion</td>
</tr>
<tr>
<td></td>
<td>2015 $2.2 billion</td>
<td>2016 $4.6 billion</td>
</tr>
<tr>
<td></td>
<td>2017 $2.5 billion</td>
<td>2018 $3.7 billion</td>
</tr>
<tr>
<td></td>
<td>2019 $4.1 billion</td>
<td>2020 $4.7 billion</td>
</tr>
<tr>
<td></td>
<td>2021 $5.2 billion</td>
<td>2022 $5.8 billion</td>
</tr>
<tr>
<td></td>
<td>2023 $6.4 billion</td>
<td>2024 $7.0 billion</td>
</tr>
<tr>
<td></td>
<td>2025 $7.6 billion</td>
<td>2026 $8.2 billion</td>
</tr>
<tr>
<td></td>
<td>2027 $8.8 billion</td>
<td>2028 $9.4 billion</td>
</tr>
<tr>
<td></td>
<td>2029 $10.0 billion</td>
<td>2030 $10.6 billion</td>
</tr>
</tbody>
</table>

Our Partnerships

We collaborate closely with country governments, multilateral institutions, bilateral agencies, nonprofits, pharmaceutical companies and private philanthropy. Strategic partnerships provide opportunities to draw upon the knowledge, expertise and resources from a diverse range of stakeholders. Through a range of partnerships, our program is unlocking new possibilities to accelerate the WHO 2020 NTD goals and the Sustainable Development Agenda.

Leverage private sector donations to maximize tax dollars

Our success is underpinned by a dynamic public-private partnership with the pharmaceutical industry, enabling USAID to carry out the largest integrated NTD program in the world, ensuring that treatments reach those in need. Leading pharmaceutical companies have made unprecedented pledges to tackle the most common NTDs by providing drugs free of charge.

- Eisai Co., Ltd.
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co. Inc.
- Merck KGaA
- Pfizer

To date: Every $1 invested by the US Government

Leverages $26 in donated medicines for mass treatment campaigns totalling $15.7 BILLION in value

Where We Work

Leverage private sector donations to maximize tax dollars

Our success is underpinned by a dynamic public-private partnership with the pharmaceutical industry, enabling USAID to carry out the largest integrated NTD program in the world, ensuring that treatments reach those in need. Leading pharmaceutical companies have made unprecedented pledges to tackle the most common NTDs by providing drugs free of charge.

- Eisai Co., Ltd.
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co. Inc.
- Merck KGaA
- Pfizer

To date: Every $1 invested by the US Government

Leverages $26 in donated medicines for mass treatment campaigns totalling $15.7 BILLION in value

Where We Work

Country Successes

USAID supported countries that have eliminated at least one disease, officially verified by the WHO:

- Lymphatic Filariasis: Cambodia (2016), Togo (2017)
- Trachoma: Cambodia (2017), Laos (2017)

LATIN AMERICA & THE CARIBBEAN
- Haiti
- Onchocerciasis Program for Elimination in the Americas (OEPA)
  - Brazil
  - Colombia
  - Ecuador
  - Guatemala
  - Mexico
  - Venezuela

AFRICA
- Benin
- Burkina Faso
- Cameroon
- Democratic Republic of the Congo
  - Ethiopia
  - Ghana
  - Guinea
  - Ivory Coast
  - Mali
  - Mozambique
  - Niger
  - Nigeria
  - Senegal
  - Sierra Leone
  - Tanzania
  - Togo
  - Uganda

ASIA
- Bangladesh
- Cambodia
- Indonesia
- Laos
- Nepal
- Philippines
- Vietnam

https://www.neglecteddiseases.gov